Glaxo's In-Licensing Binge Continues
Executive Summary
The message of GSK's recent $270 million dollar licensing deal with Adolor is that, so long as Big Pharma pipelines are suffering and patents keep expiring, late-stage products from small companies can command highly respectable prices. And GSK’s active dealmaking shows that this company, unlike many of its competitors, recognizes that late-stage products still carry enormous risk.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.